Anti-Cancer Therapies

Abstract

Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed.

1 . A method for managing pancreatic cancer in a patient, comprising:
 determining whether the patient has previously been treated with gemcitabine; and if so,   treating the patient's pancreatic cancer with a regimen that includes administration of glufosfamide.   
     
     
         2 . The method of  claim 1 , wherein the cancer is pancreatic adenocarcinoma. 
     
     
         3 . The method of  claim 1  wherein the cancer comprises a locally advanced tumor. 
     
     
         4 . The method of  claim 1 , wherein the cancer comprises a metastatic tumor. 
     
     
         5 . The method of  claim 1 , wherein the glufosfamide is administered by infusion. 
     
     
         6 . A method for second-line chemotherapy of pancreatic cancer in a patient, comprising:
 determining whether the pancreatic cancer in the patient has advanced in spite of previous therapy; and if so,   prescribing treatment of the patient's pancreatic cancer with a regimen that includes administration of glufosfamide.   
     
     
         7 . The method of  claim 6 , wherein the regimen includes administering the glufosfamide in multiple dosage cycles. 
     
     
         8 . The method of  claim 6 , wherein the regimen includes administering the glufosfamide by infusion about once every three or four weeks. 
     
     
         9 . The method of  claim 6 , wherein the regimen includes administering the glufosfamide at a dose of about 1.5 to about 6.0 g/m 2 . 
     
     
         10 . The method of  claim 6 , wherein the regimen includes administering the glufosfamide at a dose of about 1.5 to about 2.0 g/m 2  over an infusion period of 1 to 6 hours once per week. 
     
     
         11 . A kit configured for second-line chemotherapy, comprising:
 a pharmaceutical composition formulated for intravenous administration into a human subject containing a dose of glufosfamide that is effective in treating gemcitabine resistant pancreatic cancer, and   directions for use of the pharmaceutical composition as a second-line therapy for treatment of pancreatic cancer.   
     
     
         12 . The kit according to  claim 11 , comprising multiple cycles of a dose of glufosfamide selected for treatment of gemcitabine resistant pancreatic cancer. 
     
     
         13 . The kit according to  claim 11 , wherein the dose is about 1.5 to about 6.0 g/m 2 . 
     
     
         14 . The kit according to  claim 11 , wherein the dose is about 1.5 to about 2.0 g/m 2 .